PL3160500T3 - Immunogenna kompozycja clostridium difficile - Google Patents

Immunogenna kompozycja clostridium difficile

Info

Publication number
PL3160500T3
PL3160500T3 PL15733404T PL15733404T PL3160500T3 PL 3160500 T3 PL3160500 T3 PL 3160500T3 PL 15733404 T PL15733404 T PL 15733404T PL 15733404 T PL15733404 T PL 15733404T PL 3160500 T3 PL3160500 T3 PL 3160500T3
Authority
PL
Poland
Prior art keywords
immunogenic composition
clostridium difficile
difficile immunogenic
clostridium
composition
Prior art date
Application number
PL15733404T
Other languages
English (en)
Polish (pl)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of PL3160500T3 publication Critical patent/PL3160500T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL15733404T 2014-06-25 2015-06-25 Immunogenna kompozycja clostridium difficile PL3160500T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition
EP15733404.6A EP3160500B1 (en) 2014-06-25 2015-06-25 Clostridium difficile immunogenic composition
PCT/EP2015/064324 WO2015197737A1 (en) 2014-06-25 2015-06-25 Clostridium difficile immunogenic composition

Publications (1)

Publication Number Publication Date
PL3160500T3 true PL3160500T3 (pl) 2020-02-28

Family

ID=53498986

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15733404T PL3160500T3 (pl) 2014-06-25 2015-06-25 Immunogenna kompozycja clostridium difficile

Country Status (18)

Country Link
US (1) US20170218031A1 (enExample)
EP (2) EP3636278A3 (enExample)
JP (2) JP6688233B2 (enExample)
CN (1) CN106536544B (enExample)
BE (1) BE1022949B1 (enExample)
BR (1) BR112016030096B1 (enExample)
CA (1) CA2952118A1 (enExample)
CY (1) CY1122145T1 (enExample)
DK (1) DK3160500T3 (enExample)
ES (1) ES2749701T3 (enExample)
HR (1) HRP20191864T1 (enExample)
HU (1) HUE045936T2 (enExample)
LT (1) LT3160500T (enExample)
MX (1) MX374380B (enExample)
PL (1) PL3160500T3 (enExample)
PT (1) PT3160500T (enExample)
SI (1) SI3160500T1 (enExample)
WO (1) WO2015197737A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595709A4 (en) * 2017-03-15 2020-12-23 Novavax, Inc. METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE
JP7426953B2 (ja) 2018-06-19 2024-02-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
NZ263538A (en) 1993-03-23 1996-10-28 Smithkline Beecham Biolog Vaccine compositions of 3-o-deacylated monophosphoryl lipid a
JP2002514886A (ja) 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH11506332A (ja) 1995-06-02 1999-06-08 インサイト・ファーマスーティカルズ・インコーポレイテッド 全長ｃＤＮＡ配列を獲得する改良された方法
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
WO2001073030A2 (en) 2000-03-28 2001-10-04 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2005004791A2 (en) * 2002-11-08 2005-01-20 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
IN2014CN04071A (enExample) * 2011-12-08 2015-10-23 Novartis Ag
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
EP3636278A3 (en) 2020-07-15
US20170218031A1 (en) 2017-08-03
JP2020100625A (ja) 2020-07-02
BE1022949B1 (fr) 2016-10-21
PT3160500T (pt) 2019-11-11
CY1122145T1 (el) 2020-11-25
ES2749701T3 (es) 2020-03-23
CA2952118A1 (en) 2015-12-30
MX374380B (es) 2025-03-06
CN106536544B (zh) 2020-04-07
BR112016030096B1 (pt) 2023-10-03
HUE045936T2 (hu) 2020-01-28
DK3160500T3 (da) 2019-11-11
BE1022949A1 (fr) 2016-10-21
MX2016017094A (es) 2017-05-03
JP6688233B2 (ja) 2020-04-28
LT3160500T (lt) 2019-10-25
WO2015197737A1 (en) 2015-12-30
BR112016030096A2 (pt) 2017-08-22
EP3160500B1 (en) 2019-08-21
JP2017520573A (ja) 2017-07-27
HRP20191864T1 (hr) 2020-01-10
BR112016030096A8 (pt) 2021-07-06
CN106536544A (zh) 2017-03-22
EP3636278A2 (en) 2020-04-15
SI3160500T1 (sl) 2019-11-29
EP3160500A1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
PT3146065T (pt) Métodos e composições para reduzir a infecção por clostridium difficile
IL248223B (en) Compositions of vaccine
GB201501859D0 (en) Composition
GB201410905D0 (en) Composition
ZA201702401B (en) Composition with reduced immunogenicity
ZA201704464B (en) Composition
GB201403017D0 (en) Composition
GB201408167D0 (en) Compositions
IL251479A0 (en) components
PL3203988T3 (pl) Kompozycje szczepionki o zmniejszonym pienieniu
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
LT3160500T (lt) Clostridium difficile imunogeninė kompozicija
PL3217964T3 (pl) Kompozycja
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
GB201519442D0 (en) Composition
GB201420628D0 (en) Composition
GB201415483D0 (en) Composition
GB201404390D0 (en) Composition
GB201403550D0 (en) Composition
GB201402648D0 (en) Composition
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
IL250781A0 (en) preparation